Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 943

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 943
---
.

F-123

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Notes to CONDENSED Financial Statements
(Unaudited) 6. Accrued Expenses Accrued expenses consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

| ​                                          | ​ | ​ | As ofSeptember 30,2024 |   |       |   | ​ | ​ | As ofDecember 31,2023 |   |       |   | ​ |
|:-------------------------------------------|:--|:--|:-----------------------|:--|------:|:--|:--|:--|:----------------------|:--|------:|:--|:--|
| Accrued research and development expenses  | ​ | ​ | ​                      | $ | 1,008 | ​ | ​ | ​ | ​                     | $ |   574 | ​ | ​ |
| Accrued employee compensation and benefits | ​ | ​ | ​                      | ​ | 1,185 | ​ | ​ | ​ | ​                     | ​ |   942 | ​ | ​ |
| Other accrued expenses                     | ​ | ​ | ​                      | ​ | 1,044 | ​ | ​ | ​ | ​                     | ​ |    61 | ​ | ​ |
| Total accrued expenses                     | ​ | ​ | ​                      | $ | 3,237 | ​ | ​ | ​ | ​                     | $ | 1,577 | ​ | ​ |

7. Leases The Company has one operating lease pertaining to 5,969 square feet of corporate office space in Sugar Land, Texas, pursuant to a lease agreement that commenced April 1, 2022. As of September 30, 2024, the remaining term of lease was 2.92 years. The lease requires monthly lease payments that are subject to annual increases throughout the lease term. The components of lease costs, which are included within general and administrative expenses in the Company’s statements of operations were as follows (in thousands):

| ​                    
 ​                    
 Lease costs:         | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For the Nine MonthsEnded September 30, 
 2024                                   
 ​                                      | ​ |   ​ | ​ | ​ 
 ​ | ​ 
 ​ | 2023 
 ​    | ​ |   ​ | ​ | ​ 
 ​ 
 ​ |
|:---------------------|: